دورية أكاديمية
Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
| العنوان: | Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer. |
|---|---|
| المؤلفون: | Korkmaz ET; Aksaray University Education and Research Hospital, Department of Chest Diseases, Turkey. Electronic address: etugce.korkmaz@hacettepe.edu.tr., Koksal D; Hacettepe University School of Medicine, Department of Chest Diseases, Turkey., Aksu F; Atatürk Chest Diseases and Chest Surgery Education and Research Hospital, Department of Chest Diseases., Dikmen ZG; Hacettepe University, Department of Medical Biochemistry, Turkey., Icen D; Hacettepe University, Department of Statistics, Turkey., Maden E; Yuzuncu Yil Hospital, Department of Chest Diseases, Turkey., Onder S; Hacettepe University, Department of Pathology, Turkey., Akbiyik F; Hacettepe University, Department of Medical Biochemistry, Turkey., Emri S; Altinbaş University School of Medicine, Department of Chest Diseases, Turkey. |
| المصدر: | Clinical biochemistry [Clin Biochem] 2018 Aug; Vol. 58, pp. 15-19. Date of Electronic Publication: 2018 May 02. |
| نوع المنشور: | Clinical Trial; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: United States NLM ID: 0133660 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2933 (Electronic) Linking ISSN: 00099120 NLM ISO Abbreviation: Clin Biochem Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Tarrytown, NY : Elsevier Science Original Publication: [Toronto] Canadian Society of Clinical Chemists. |
| مواضيع طبية MeSH: | Lung Neoplasms*/blood , Lung Neoplasms*/classification , Lung Neoplasms*/diagnosis , Lung Neoplasms*/pathology , Small Cell Lung Carcinoma*/blood , Small Cell Lung Carcinoma*/classification , Small Cell Lung Carcinoma*/diagnosis , Small Cell Lung Carcinoma*/pathology, Antigens, Neoplasm/*blood , Biomarkers, Tumor/*blood , Keratin-19/*blood , Neoplasm Proteins/*blood , Peptide Fragments/*blood , Proteins/*metabolism, Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Recombinant Proteins/blood ; WAP Four-Disulfide Core Domain Protein 2 |
| مستخلص: | Background and Aim: Early diagnosis and histological subtyping are important issues in the management of patients with lung cancer (LC). The aim of this study is to investigate the diagnostic value of a panel of serum tumor markers in newly diagnosed patients with LC. Methods: Venous blood samples were collected from 99 patients with LC (42 adenocarcinoma, 35 squamous, and 22 small cell carcinoma) and 30 patients with benign lung disease. Progastrin releasing peptide (ProGRP), squamous cell carcinoma antigen (SCCAg), cytokeratin 19-fragments (CYFRA 21.1), human epididymis protein 4 (HE4), Chromogranin A (CgA) and neuron specific enolase (NSE) levels were measured. The diagnostic value of the biomarkers was assessed with ROC curve analyses; the area under the curve (AUC) was calculated. Results: Serum CYFRA 21.1, ProGRP, SCCAg, NSE levels were significantly higher in LC patients. While ProGRP levels were higher (p = 0.009) in SCLC; CYFRA 21.1 and SCCAg levels were higher in NSCLC (p = 0.019 and p = 0.001, respectively). The sensitivity and specificity of tumor markers were 72%, 83% for CYFRA 21.1; 70%, 57% for HE4; 18%, 93% for ProGRP; 43%, 77% for SCCAg; 54%, 53% for CgA; 73%, 50% for NSE. CYFRA 21.1 (p < 0.001, r = 0.394), HE4 (p = 0.014, r = 0.279) and CgA (p = 0.023, r = 0.259) levels were positively correlated with tumor stage in NSCLC. CgA levels were significantly higher in extensive stage SCLC (p = 0.004). CYFRA 21.1 had the highest diagnostic value for LC (AUC = 0.865). When it is combined with HE4, diagnostic value increased (AUC = 0.899). ProGRP had the highest diagnostic value (AUC = 0.875, p < 0.001) for discriminating SCLC from NSCLC. Conclusion: A panel of three tumor markers CYFRA 21.1, HE4 and ProGRP may play a role for discriminating LC from benign lung disease and subtyping as SCLC. (Copyright © 2018 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Biomarkers; Diagnosis; Lung cancer; Tumor markers |
| المشرفين على المادة: | 0 (Antigens, Neoplasm) 0 (Biomarkers, Tumor) 0 (Keratin-19) 0 (Neoplasm Proteins) 0 (Peptide Fragments) 0 (Proteins) 0 (Recombinant Proteins) 0 (WAP Four-Disulfide Core Domain Protein 2) 0 (WFDC2 protein, human) 0 (antigen CYFRA21.1) 0 (pro-gastrin-releasing peptide (31-98)) |
| تواريخ الأحداث: | Date Created: 20180506 Date Completed: 20180829 Latest Revision: 20220410 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.clinbiochem.2018.05.001 |
| PMID: | 29729229 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!